|
CA1327358C
(en)
|
1987-11-17 |
1994-03-01 |
Morio Fujiu |
Fluoro cytidine derivatives
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
|
AU671491B2
(en)
|
1992-12-18 |
1996-08-29 |
F. Hoffmann-La Roche Ag |
N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
|
|
TW254946B
(enExample)
|
1992-12-18 |
1995-08-21 |
Hoffmann La Roche |
|
|
UA41909C2
(uk)
|
1994-07-22 |
2001-10-15 |
Елі Ліллі Енд Компані |
Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
|
|
US5476932A
(en)
|
1994-08-26 |
1995-12-19 |
Hoffmann-La Roche Inc. |
Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
|
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
WO1997017329A1
(en)
|
1995-11-07 |
1997-05-15 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
|
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
|
US6002008A
(en)
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
|
US6251912B1
(en)
|
1997-08-01 |
2001-06-26 |
American Cyanamid Company |
Substituted quinazoline derivatives
|
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
|
US6297258B1
(en)
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
|
PL201475B1
(pl)
|
1998-09-29 |
2009-04-30 |
Wyeth Corp |
Podstawione 3-cyjanochinoliny jako inhibitory białkowych kinaz tyrozynowych
|
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
|
NZ519984A
(en)
|
2000-01-07 |
2004-03-26 |
Transform Pharmaceuticals Inc |
High-throughput formation, identification, and analysis of diverse solid-forms
|
|
US6384051B1
(en)
|
2000-03-13 |
2002-05-07 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps
|
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
|
DK1318837T3
(da)
|
2000-08-11 |
2005-01-10 |
Wyeth Corp |
Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom
|
|
TWI286074B
(en)
|
2000-11-15 |
2007-09-01 |
Wyeth Corp |
Pharmaceutical composition containing CCI-779 as an antineoplastic agent
|
|
PL363991A1
(en)
|
2001-04-06 |
2004-11-29 |
Wyeth |
Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
|
|
TWI233359B
(en)
|
2001-04-06 |
2005-06-01 |
Wyeth Corp |
Pharmaceutical composition for treating neoplasm
|
|
TWI296196B
(en)
|
2001-04-06 |
2008-05-01 |
Wyeth Corp |
Antineoplastic combinations
|
|
ZA200603888B
(en)
|
2001-06-01 |
2007-05-30 |
Wyeth Corp |
Antineoplastic combinations
|
|
IL158800A0
(en)
|
2001-06-01 |
2004-05-12 |
Wyeth Corp |
Antineoplastic combinations
|
|
UA77200C2
(en)
|
2001-08-07 |
2006-11-15 |
Wyeth Corp |
Antineoplastic combination of cci-779 and bkb-569
|
|
PL370137A1
(en)
|
2001-11-27 |
2005-05-16 |
Wyeth Holdings Corporation |
3-cyanoquinolines as inhibitors of egf-r and her2 kinases
|
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
|
DE60310922T2
(de)
|
2002-06-05 |
2007-10-11 |
Cedars-Sinai Medical Center, Los Angeles |
Gefitinib (iressa) zur behandlung von krebs
|
|
AU2003248813A1
(en)
|
2002-07-05 |
2004-01-23 |
Beth Israel Deaconess Medical Center |
Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
|
|
US20040209930A1
(en)
|
2002-10-02 |
2004-10-21 |
Carboni Joan M. |
Synergistic methods and compositions for treating cancer
|
|
CL2004000016A1
(es)
|
2003-01-21 |
2005-04-15 |
Wyeth Corp |
Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
|
|
UA83484C2
(uk)
|
2003-03-05 |
2008-07-25 |
Уайт |
Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
|
|
EP1615640B1
(en)
|
2003-04-22 |
2007-01-24 |
Wyeth |
Antineoplastic combinations
|
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
RS52625B
(sr)
|
2003-07-23 |
2013-06-28 |
Bayer Healthcare Llc |
Fluoro supstituisana omega-karboksiaril difenil urea za lečenje i prevenciju bolesti i stanja bolesti
|
|
US20050025825A1
(en)
|
2003-07-31 |
2005-02-03 |
Xanodyne Pharmacal, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
|
EP1648516A2
(en)
|
2003-08-01 |
2006-04-26 |
Wyeth Holdings Corporation |
Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
|
|
JP2007502819A
(ja)
|
2003-08-19 |
2007-02-15 |
ワイス・ホールディングズ・コーポレイション |
４−アミノ−３−キノリンカルボニトリルの調製方法
|
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
|
MXPA06002846A
(es)
|
2003-09-15 |
2006-06-14 |
Wyeth Corp |
Quinolinas sustituidas como inhibidores de la enzima de la proteina tirosina cinasa.
|
|
TWI372066B
(en)
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
|
US20050142192A1
(en)
|
2003-10-15 |
2005-06-30 |
Wyeth |
Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
|
|
WO2005044091A2
(en)
|
2003-11-05 |
2005-05-19 |
Board Of Regents, The University Of Texas System |
Diagnostic and therapeutic methods and compositions involving pten and breast cancer
|
|
TW200526684A
(en)
|
2003-11-21 |
2005-08-16 |
Schering Corp |
Anti-IGFR1 antibody therapeutic combinations
|
|
AR047988A1
(es)
|
2004-03-11 |
2006-03-15 |
Wyeth Corp |
Combinaciones antineoplásicas de cci-779 y rituximab
|
|
PT1733056E
(pt)
|
2004-03-31 |
2013-08-29 |
Gen Hospital Corp |
Método para determinar a responsividade do cancro a tratamentos visando o receptor do factor de crescimento epidérmico
|
|
MX2007000944A
(es)
|
2004-07-23 |
2007-04-13 |
Astrazeneca Ab |
Metodo para pronosticar la sensibilidad de un tumor a farmacos del receptor erbb.
|
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
|
TW200616612A
(en)
|
2004-10-08 |
2006-06-01 |
Wyeth Corp |
Method for the teatment of polycystic kidney disease field of invention
|
|
TW200626610A
(en)
|
2004-10-13 |
2006-08-01 |
Wyeth Corp |
Analogs of 17-hydroxywortmannin as PI3K inhibitors
|
|
WO2006044748A2
(en)
|
2004-10-15 |
2006-04-27 |
Monogram Biosciences, Inc. |
RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
|
|
GB0501999D0
(en)
|
2005-02-01 |
2005-03-09 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
|
ZA200706804B
(en)
|
2005-02-03 |
2008-10-29 |
Gen Hospital Corp |
Method for treating gefitinib resistant cancer
|
|
WO2006081985A1
(en)
|
2005-02-04 |
2006-08-10 |
F. Hoffmann-La Roche Ag |
Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
|
|
US20090047278A1
(en)
|
2005-02-28 |
2009-02-19 |
Eisai R & D Management Co., Ltd. |
Novel Combinational Use of Sulfonamide Compound
|
|
US8105768B2
(en)
|
2005-03-09 |
2012-01-31 |
Abbott Laboratories |
Methods of identifying patients for treatment with HER-2/neu inhibitors based on detection of HER-2/neu and TOP2A gene copy number
|
|
GB0504994D0
(en)
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
|
KR20080002826A
(ko)
|
2005-04-14 |
2008-01-04 |
와이어쓰 |
게피티니브 내성 환자에서의 표피 성장 인자 수용체（ｅｇｆｒ） 키나제 억제제의 용도
|
|
US20110045459A1
(en)
|
2005-04-21 |
2011-02-24 |
Mischel Paul S |
Molecular determinants of EGFR kinase inhibitor response in glioblastoma
|
|
AR056328A1
(es)
|
2005-04-28 |
2007-10-03 |
Wyeth Corp |
TANAPROGET MICRONIZADO, COMPOSICIONES Y MÉTODOS PARA SU PREPARACIoN
|
|
AU2006245421A1
(en)
|
2005-05-12 |
2006-11-16 |
Pfizer Inc. |
Anticancer combination therapy using sunitinib malate
|
|
MX2007014773A
(es)
|
2005-05-25 |
2008-02-20 |
Wyeth Corp |
Metodo para preparar 3-ciano-quinolinas e intermedios hechos de esta forma.
|
|
JP2008545688A
(ja)
|
2005-05-25 |
2008-12-18 |
ワイス |
置換３−シアノキノリン並びにその中間体を合成する方法
|
|
DE102005053679A1
(de)
|
2005-06-24 |
2006-12-28 |
Bayer Healthcare Ag |
Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
|
|
GT200600307A
(es)
|
2005-07-15 |
2008-04-24 |
|
Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina
|
|
WO2007015569A1
(ja)
|
2005-08-01 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を予測する方法
|
|
EP1925676A4
(en)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
|
|
NZ566387A
(en)
|
2005-10-05 |
2010-05-28 |
Astrazeneca Uk Ltd |
Method to predict or monitor the response of a patient to an ErbB receptor drug by screening for mutations in an ErbB receptor
|
|
WO2007050495A2
(en)
|
2005-10-26 |
2007-05-03 |
Children's Medical Center Corporation |
Method to prognose response to anti-egfr therapeutics
|
|
KR101354828B1
(ko)
|
2005-11-04 |
2014-02-18 |
와이어쓰 엘엘씨 |
ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
|
|
AR058505A1
(es)
|
2005-11-04 |
2008-02-06 |
Wyeth Corp |
Combinaciones antineoplasicas de temsirolimus y malato de sunitinib
|
|
SI1948180T1
(sl)
|
2005-11-11 |
2013-06-28 |
Boehringer Ingelheim International Gmbh |
Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
|
|
PL1951274T3
(pl)
|
2005-11-24 |
2010-05-31 |
Aicuris Gmbh & Co Kg |
Parapoksywirusy w kombinacji z klasycznymi cytotoksycznymi środkami chemioterapeutycznymi jako biochemioterapia do leczenia raka
|
|
AU2006331688A1
(en)
|
2005-12-22 |
2007-07-05 |
Wyeth |
Oral formulations comprising tigecycline
|
|
WO2007095038A2
(en)
|
2006-02-09 |
2007-08-23 |
Novartis Ag |
Mutations and polymorphisms of erbb2
|
|
TW200806282A
(en)
|
2006-05-05 |
2008-02-01 |
Wyeth Corp |
Solid dosage formulations
|
|
CN103424541B
(zh)
|
2006-05-18 |
2018-01-30 |
分子压型学会股份有限公司 |
确定针对病状的个性化医疗介入的系统和方法
|
|
TW200808728A
(en)
|
2006-05-23 |
2008-02-16 |
Wyeth Corp |
Method of preparing 4-halogenated quinoline intermediates
|
|
JP5399900B2
(ja)
|
2006-06-30 |
2014-01-29 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Ｉｇｆｂｐ２インヒビター
|
|
DK2068880T3
(da)
|
2006-09-18 |
2012-07-23 |
Boehringer Ingelheim Int |
Fremgangsmåde til behandling af cancer, der huser EGFR-mutationer
|
|
EP2077819A4
(en)
|
2006-09-28 |
2011-05-25 |
Follica Inc |
PROCESSES, KITS AND COMPOSITIONS FOR PRODUCING NEW HAIRFOLLICLES AND GROWING HAIR
|
|
EP2073823A1
(en)
|
2006-10-13 |
2009-07-01 |
Medigene AG |
Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
|
|
EP2121018A2
(en)
|
2006-12-13 |
2009-11-25 |
Schering Corporation |
Treating cancer with anti-igf1r antibody 19d12=sch 717454
|
|
CN102123712B
(zh)
|
2006-12-13 |
2014-03-19 |
默沙东公司 |
使用igf1r抑制剂治疗癌症的方法
|
|
US8247421B2
(en)
|
2006-12-21 |
2012-08-21 |
Vertex Pharmaceuticals Incorporated |
5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
|
|
BRPI0806543A2
(pt)
|
2007-01-12 |
2014-04-22 |
Wyeth Corp |
Composições de comprimido em comprimido
|
|
CA2676244C
(en)
|
2007-01-25 |
2017-01-17 |
Kwok-Kin Wong |
Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
|
|
JP5284967B2
(ja)
|
2007-02-01 |
2013-09-11 |
武田薬品工業株式会社 |
打錠障害を生じない錠剤製剤
|
|
WO2008121467A2
(en)
|
2007-02-28 |
2008-10-09 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for treating cancer
|
|
GB0706633D0
(en)
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
Combination
|
|
ES2529790T3
(es)
|
2007-04-13 |
2015-02-25 |
Dana-Farber Cancer Institute, Inc. |
Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
|
|
EP2145188A4
(en)
|
2007-04-19 |
2010-06-30 |
Wellstat Biologics Corp |
DETECTION OF HER2 / NEU PROTEIN FROM UNISISIONED CIRCULATING CANCER CELLS AND TREATMENT
|
|
WO2008136838A1
(en)
|
2007-05-04 |
2008-11-13 |
Trustees Of Dartmouth College |
Novel amide derivatives of cddo and methods of use thereof
|
|
US20110014117A1
(en)
|
2007-06-28 |
2011-01-20 |
Schering Corporation |
Anti-igf1r
|
|
EP3067054B1
(en)
|
2007-09-10 |
2020-12-30 |
Boston Biomedical, Inc. |
Novel compositions and methods for cancer treatment
|
|
JP2010540459A
(ja)
|
2007-09-24 |
2010-12-24 |
トラガラ ファーマシューティカルズ，インク． |
Ｃｏｘ‐２阻害薬及びｅｇｆｒ［ｅｒｂｂ１］とｈｅｒ‐２［ｅｒｂｂ２］の二重阻害薬を用いた癌を治療するための併用療法
|
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
|
WO2009055343A2
(en)
|
2007-10-22 |
2009-04-30 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
AU2008325219A1
(en)
|
2007-11-05 |
2009-05-14 |
Puretech Ventures |
Methods, kits, and compositions for administering pharmaceutical compounds
|
|
JP2011505873A
(ja)
|
2007-12-18 |
2011-03-03 |
シェーリング コーポレイション |
抗ｉｇｆ１ｒ療法に対する感受性のバイオマーカー
|
|
US20100297118A1
(en)
|
2007-12-27 |
2010-11-25 |
Macdougall John |
Therapeutic Cancer Treatments
|
|
WO2009105234A2
(en)
|
2008-02-19 |
2009-08-27 |
Combinatorx, Incorporated |
Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
|
|
WO2009108637A1
(en)
|
2008-02-25 |
2009-09-03 |
Prometheus Laboratories, Inc. |
Drug selection for breast cancer therapy using antibody-based arrays
|
|
US20100081632A1
(en)
|
2008-03-06 |
2010-04-01 |
Odyssey Thera, Inc. |
High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
|
|
CA2718918A1
(en)
|
2008-03-25 |
2009-11-26 |
Schering Corporation |
Methods for treating or preventing colorectal cancer
|
|
EP2977468B1
(en)
|
2008-03-27 |
2019-06-19 |
Vascular Biosciences, Inc. |
Methods of novel therapeutic candidate identification through gene expression analysis in pulmonary arterial hypertension
|
|
US20090246198A1
(en)
|
2008-03-31 |
2009-10-01 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
|
CA2725390C
(en)
|
2008-04-08 |
2014-09-23 |
Syndax Pharmaceuticals, Inc. |
Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
|
|
DK2276493T3
(da)
|
2008-04-18 |
2019-01-02 |
Reata Pharmaceuticals Inc |
Antioxidative inflammationsmodulatorer: oleanolsyrederivater med amino- og andre modifikationer ved c-17
|
|
TW201004627A
(en)
|
2008-04-18 |
2010-02-01 |
Reata Pharmaceuticals Inc |
Antioxidant inflammation modulators: novel derivatives of oleanolic acid
|
|
WO2009129548A1
(en)
|
2008-04-18 |
2009-10-22 |
Reata Pharmaceuticals, Inc. |
Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
|
|
EA022588B1
(ru)
|
2008-04-18 |
2016-01-29 |
Ритэ Фамэсутикл, Инк. |
Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце
|
|
MX2010011435A
(es)
|
2008-04-18 |
2011-01-25 |
Reata Pharmaceuticals Inc |
Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
|
|
US20110129456A1
(en)
|
2008-05-05 |
2011-06-02 |
Yaolin Wang |
Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
|
|
WO2009151910A2
(en)
|
2008-05-25 |
2009-12-17 |
Wyeth |
Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
|
|
CA2725598C
(en)
|
2008-06-17 |
2013-10-08 |
Wyeth Llc |
Antineoplastic combinations containing hki-272 and vinorelbine
|
|
AU2009274037B2
(en)
|
2008-07-22 |
2015-07-09 |
Trustees Of Dartmouth College |
Monocyclic cyanoenones and methods of use thereof
|
|
MX2011001318A
(es)
|
2008-08-04 |
2011-03-04 |
Wyeth Llc |
Combinaciones antineoplasicas de 4-anilino-3-cianoquinolinas y capecitabina.
|
|
WO2010030835A2
(en)
|
2008-09-11 |
2010-03-18 |
Wyeth Llc |
Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
|
|
WO2010045318A2
(en)
|
2008-10-14 |
2010-04-22 |
Caris Mpi, Inc. |
Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
|
|
WO2010048477A2
(en)
|
2008-10-24 |
2010-04-29 |
Wyeth Llc |
Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
|
|
KR20110086844A
(ko)
|
2008-11-07 |
2011-08-01 |
엔즌 파마슈티칼스, 인코포레이티드 |
Ｅｒｂｂ－３（ｈｅｒ３）－선택적 조합 요법
|
|
WO2010085845A1
(en)
|
2009-01-28 |
2010-08-05 |
The University Of Queensland |
Cancer therapy and/or diagnosis
|
|
US20120130144A1
(en)
|
2009-02-04 |
2012-05-24 |
Bipar Sciences, Inc. |
Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor
|
|
WO2010098627A2
(ko)
|
2009-02-27 |
2010-09-02 |
한올바이오파마주식회사 |
약제학적 제제
|
|
AU2010221818A1
(en)
|
2009-03-11 |
2011-10-06 |
Auckland Uniservices Limited |
Prodrug forms of kinase inhibitors and their use in therapy
|
|
EP2416774B1
(en)
|
2009-04-06 |
2015-11-04 |
Wyeth LLC |
Treatment regimen utilizing neratinib for breast cancer
|
|
AR076053A1
(es)
|
2009-04-14 |
2011-05-18 |
Schering Corp |
Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
|
|
WO2010124009A2
(en)
|
2009-04-21 |
2010-10-28 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
JP5918693B2
(ja)
|
2009-05-05 |
2016-05-18 |
ダナ ファーバー キャンサー インスティテュート インコーポレイテッド |
Ｅｇｆｒ阻害剤及び疾患の治療方法
|
|
CA2766067A1
(en)
|
2009-07-02 |
2011-01-06 |
Wyeth Llc |
3-cyanoquinoline tablet formulations and uses thereof
|
|
WO2011008053A2
(ko)
|
2009-07-17 |
2011-01-20 |
한올바이오파마주식회사 |
Ｎ,ｎ-디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
|
|
KR20110007985A
(ko)
|
2009-07-17 |
2011-01-25 |
한올바이오파마주식회사 |
Ｎ,ｎ―디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
|
|
WO2011025269A2
(ko)
|
2009-08-25 |
2011-03-03 |
한올바이오파마주식회사 |
메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
|
WO2011025271A2
(ko)
|
2009-08-25 |
2011-03-03 |
한올바이오파마주식회사 |
메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
|
WO2011025267A2
(ko)
|
2009-08-25 |
2011-03-03 |
한올바이오파마주식회사 |
메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
|
EP2470212A4
(en)
|
2009-10-01 |
2013-12-04 |
Csl Ltd |
METHOD FOR TREATING POSITIVE PHILADELPHIA CHROMOSOME LEUKEMIA
|
|
NZ599763A
(en)
|
2009-11-09 |
2014-06-27 |
Wyeth Llc |
Tablet formulations of neratinib maleate
|
|
EP2498751B1
(en)
|
2009-11-09 |
2019-04-03 |
Wyeth LLC |
Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
|
|
KR101806323B1
(ko)
|
2009-11-13 |
2017-12-07 |
다이이치 산쿄 유럽 게엠베하 |
Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법
|
|
US20130012465A1
(en)
|
2009-12-07 |
2013-01-10 |
Boehringer Ingelheim International Gmbh |
Bibw 2992 for use in the treatment of triple negative breast cancer
|
|
EP2510121A1
(en)
|
2009-12-11 |
2012-10-17 |
Wyeth LLC |
Phosphatidylinositol-3-kinase pathway biomarkers
|
|
ES2638821T3
(es)
|
2010-01-13 |
2017-10-24 |
Wyeth Llc |
Un punto de corte en la expresión de la proteína PTEN que identifica tumores con precisión y es predictivo de la respuesta a fármacos a un inhibidor pan-ErbB
|